SCHEMBL5599080

SCHEMBL5599080

CCCOC(=O)CC(C)c1cccc(C(C)C)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
LMNA P02545 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
GABRA1 P14867 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
GABRB1 P18505 1/20 0.49
GABRG2 P18507 1/20 0.49
PTGS1 P23219 1/20 0.49
SLC6A2 P23975 1/20 0.49
HTR2C P28335 1/20 0.49
GABRB3 P28472 1/20 0.49
GABRA5 P31644 1/20 0.49
GABRA3 P34903 1/20 0.49
HTR2B P41595 1/20 0.49
GABRA2 P47869 1/20 0.49
GABRB2 P47870 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5598708 0.88 TSHR (0.52) FAAHCA1CA2LMNACYP1A2
SCHEMBL28739302 0.82 GABRA1 (0.55) FAAHCA1CA2LMNACYP1A2
SCHEMBL5598892 0.81 MAPK1 (0.55) FAAHCA1CA2LMNACYP1A2
SCHEMBL5599052 0.78 LMNA (0.50) FAAHCA1CA2LMNACYP1A2
SCHEMBL5598458 0.78 MAPK1 (0.46) FAAHCA1CA2LMNACYP1A2
SCHEMBL5598758 0.75 MAPK1 (0.46) FAAHCA1CA2LMNACYP1A2
SCHEMBL5598497 0.74 TSHR (0.44) FAAHCA1CA2LMNACYP1A2
Propofol SCHEMBL29176295 0.74 GABRA1 (0.81) FAAHCA1CA2LMNACYP1A2
SCHEMBL27618808 0.73 NLRP3 (0.42) LMNACYP1A2CYP3A4HPGDTSHR
SCHEMBL5598826 0.73 MAPK1 (0.47) FAAHCA1CA2LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7226946-B2 Substituted phenol compounds useful for anesthesia and sedation THERAVANCE, INC. (US) 2007-06-05 US disclosed
US-20050032753-A1 Substituted phenol compounds useful for anesthesia and sedation THERAVANCE BIOPHARMA R&D IP, LLC 2005-02-10 US disclosed
US-6815555-B2 CONTAINING AN ESTER, ANHYDRIDE, PHOSPHONATE OR THIOESTER GROUP THERAVANCE, INC. 2004-11-09 US disclosed
EP-1430017-A2 SUBSTITUTED PHENOL COMPOUNDS USEFUL FOR ANESTHESIA AND SEDATION Theravance, Inc. (US) 2004-06-23 EP disclosed
US-20030119790-A1 Substituted phenol compounds useful for anesthesia and sedation THERAVANCE BIOPHARMA R&D IP, LLC 2003-06-26 US disclosed
WO-2003026632-A2 SUBSTITUTED PHENOL COMPOUNDS USEFUL FOR ANESTHESIA AND SEDATION THERAVANCE, INC. (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032753-A1 Substituted phenol compounds useful for anesthesia and sedation OPRL1, PNMT, PPARG FAAH 140/4885CA1 1352/4885CA2 820/4885
US-20030119790-A1 Substituted phenol compounds useful for anesthesia and sedation OPRL1, PNMT, PPARG FAAH 140/4885CA1 1352/4885CA2 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.